Published in J Immunol on May 01, 2008
Therapeutic antibodies directed at G protein-coupled receptors. MAbs (2010) 1.41
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine (2010) 1.33
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One (2011) 1.28
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine (2013) 1.02
Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials (2012) 0.99
Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog (2014) 0.98
Follicular dendritic cells in health and disease. Front Immunol (2012) 0.90
A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine (2012) 0.89
Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology (2016) 0.88
Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest (2016) 0.87
Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine (2009) 0.87
A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol (2013) 0.87
Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. MAbs (2014) 0.84
Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine (2011) 0.84
A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine (2015) 0.82
Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization. PLoS One (2015) 0.81
Engaging adaptive immunity with biomaterials. J Mater Chem B Mater Biol Med (2014) 0.81
Engineering virus-like particles as vaccine platforms. Curr Opin Virol (2016) 0.79
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform. Curr Opin Virol (2015) 0.79
Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2014) 0.77
Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. PLoS One (2015) 0.77
Autologous albumin enhances the humoral immune response to capsular polysaccharide covalently coattached to bacteria-sized latex beads. Eur J Immunol (2014) 0.75
Immunological tolerance as a barrier to protective HIV humoral immunity. Curr Opin Immunol (2017) 0.75
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature (1994) 4.36
Induction of self-tolerance in mature peripheral B lymphocytes. Nature (1989) 4.02
Contribution of receptor editing to the antibody repertoire. Science (2001) 3.45
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J Exp Med (2006) 3.16
Identification of anergic B cells within a wild-type repertoire. Immunity (2006) 3.07
The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev (1987) 2.56
Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A (1976) 2.34
Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med (1994) 2.23
Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med (2004) 2.23
Transgenic mice and analysis of B-cell tolerance. Annu Rev Immunol (1992) 2.15
Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med (1994) 2.15
Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol (2004) 2.10
B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol (2007) 2.08
B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J Exp Med (2003) 1.89
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines (2007) 1.79
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Lipid rafts and B-cell activation. Nat Rev Immunol (2002) 1.68
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol (1989) 1.54
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol (2002) 1.48
Studies on the immunogenicity and tolerogenicity of T-independent antigens. J Immunol (1983) 1.33
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A (1999) 1.31
Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine (2006) 1.19
Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med (1997) 1.18
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur J Immunol (1993) 1.11
Igkappa allelic inclusion is a consequence of receptor editing. J Exp Med (2007) 1.11
Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci U S A (1994) 1.11
Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov (2004) 1.05
Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med (2007) 1.03
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol (2003) 1.03
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol (2004) 1.01
Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains. J Immunol (2003) 0.99
Receptor editing in B cells. Adv Immunol (2000) 0.98
Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. J Immunol (1990) 0.96
Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. Vaccine (2004) 0.80
In vivo survival of autoreactive B cells: characterization of long-lived B cells. J Immunol (2000) 0.79
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A (2006) 2.64
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2003) 2.58
Papillomaviruses infect cells via a clathrin-dependent pathway. Virology (2003) 2.47
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A (2004) 2.43
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe (2010) 2.24
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol (2006) 2.16
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A (2009) 1.90
Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog (2012) 1.76
Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol (2008) 1.73
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst (2011) 1.71
Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog (2008) 1.69
Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res (2003) 1.55
Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol (2009) 1.49
Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A (2006) 1.48
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol (2002) 1.48
Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer (2008) 1.46
Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) (2012) 1.46
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest (2012) 1.37
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine (2010) 1.33
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32
Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis (2009) 1.29
Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection. J Virol (2013) 1.29
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine (2005) 1.19
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine (2005) 1.14
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol (2012) 1.13
Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China. Int J Cancer (2006) 1.12
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology (2006) 1.11
Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol (2007) 1.08
The role of furin in papillomavirus infection. Future Microbiol (2009) 1.06
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst (2002) 1.03
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol (2003) 1.03
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol (2004) 1.01
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine (2012) 0.97
Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer (2011) 0.95
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol (2005) 0.94
Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine (2009) 0.94
p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis (2008) 0.94
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine (2006) 0.94
In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system. Cancer Prev Res (Phila) (2011) 0.93
Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine (2006) 0.92
Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol Immunother (2009) 0.92
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol (2007) 0.92
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology (2012) 0.89
Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. J Virol (2013) 0.87
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother (2013) 0.87
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol (2007) 0.87
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol (2011) 0.86
Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res (2007) 0.86
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer (2006) 0.86
A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. Int J Antimicrob Agents (2008) 0.82
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine (2003) 0.82
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol (2014) 0.82
Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine (2011) 0.81
A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol (2004) 0.80
Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother (2014) 0.77
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother (2014) 0.75